Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

(2012) N. Irwin et al.   DIABETOLOGIA

Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides

(2011) J. F. Rehfeld   Acta Physiologica

Impaired Insulin Secretion and Enhanced Insulin Sensitivity in Cholecystokinin-Deficient Mice

(2011) C.-M. Lo et al.   DIABETES

Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice

(2010) I. A. Montgomery et al.   DIABETES OBESITY & METABOLISM

GIP increases human adipocyte LPL expression through CREB and TORC2-mediatedtrans-activation of theLPLgene

(2010) Su-Jin Kim et al.   JOURNAL OF LIPID RESEARCH

Therapeutic potential for GIP receptor agonists and antagonists

(2009) Nigel Irwin et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

(2009) Barry D. Kerr et al.   BIOCHEMICAL PHARMACOLOGY

The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents

(2009) Hyeon-Kyu Lee et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

(2009) N. Irwin et al.   DIABETOLOGIA

Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice

(2008) Frank Isken et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

(Pro3)GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy

(2008) P L McClean et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice

(2008) Nigel Irwin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effects of Euglycemic Hyperinsulinemia and Lipid Infusion on Circulating Cholecystokinin

(2008) M. O. Weickert et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice

(2008) Nigel Irwin et al.   PEPTIDES

Vaccination against GIP for the Treatment of Obesity

(2008) Alma Fulurija et al.   PLoS One

PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement

(2007) I Verbaeys et al.   BRITISH JOURNAL OF PHARMACOLOGY